Discovery of novel dual-targeting inhibitors against PLK1-PBD and PLK4-PB3: structure-guided pharmacophore modelling, virtual screening, molecular docking, molecular dynamics simulation, and biological evaluation
Aberrant expression of PLK1 and PLK4 is closely associated with tumourigenesis, and their simultaneous inhibition can effectively suppress tumour proliferation. In this study, we successfully identified peptide inhibitors (Peptides 1–5) capable of simultaneously targeting PLK1-PBD and PLK4-PB3 via p...
Saved in:
| Main Authors: | Changhao Zhao, Hanying Wu, Huajing Liu, Hui Dong, Miao-Miao Niu, Kun Shi, Fengzhen Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14756366.2025.2522810 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Discovery of a novel PLK1 inhibitor with high inhibitory potency using a combined virtual screening strategy
by: Zhen Xu, et al.
Published: (2025-12-01) -
The status of p53 affects the efficacy of PLK1 inhibitor BI6727 in prostate cancer cells
by: Wenjing Li, et al.
Published: (2025-07-01) -
PLK1 inhibition impairs erythroid differentiation
by: Peijun Jia, et al.
Published: (2024-12-01) -
MLN0905 effectively kills gemcitabine-resistant pancreatic cancer cells by targeting PLK1
by: Min Lin, et al.
Published: (2025-07-01) -
Non‐canonical cMet regulation by vimentin mediates Plk1 inhibitor–induced apoptosis
by: Ratnakar Singh, et al.
Published: (2019-04-01)